medigraphic.com
Colegio de Medicina Interna de México.

2008, Número 4

<< Anterior Siguiente >>

Med Int Mex 2008; 24 (4)


Complicaciones metabólicas y cardiovasculares de la infección por VIH

Villegas MA, Torres EID

Idioma: Español
Referencias bibliográficas: 66
Paginas: 294-303
Archivo PDF: 210.66 Kb.


RESUMEN

La tasa de supervivencia y la calidad de vida de los pacientes con infección por VIH han mejorado notablemente con el tratamiento antirretroviral altamente activo; sin embargo, su indicación se ha relacionado con el síndrome metabólico: lipodistrofia-lipoatrofia, resistencia a la insulina y diabetes mellitus tipo 2 que, junto con otros factores de riesgo preexistentes, contribuyen al incremento de la morbilidad y mortalidad por enfermedades cardiovasculares como: lesión endotelial, pericardiopatías, endocarditis, miocarditis, miocardiopatía dilatada, coronariopatía, hipertensión arterial sistémica, hipertensión pulmonar, toxicidad por fármacos, tumores relacionados con el SIDA y enfermedades tromboembólicas, observadas en estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Inmune Defic Syndr Hum Retrovirol 1998;18(2):145- 54.

  2. Hadigan C, Meigs JB, Corcoran C, Rietschel P, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32(1):130-9.

  3. Torre D, Speranza F, Martegani R. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med 2005;6(2):66-78.

  4. Hajjar LA, Calderaro D, Yu PC, Giuliano I, et al. Cardiovascular manifestations in patients infected with the human immunodeficiency virus. Arq Bras Cardiol 2005;85(5):363-77.

  5. Fichtenbaum CJ. Coronary heart disease risk, dyslipidemia, and management in HIV-Infected persons. HIV Clin Trials 2004;5(6):416-33.

  6. Murphy RL, Barbaro G. Clinical and biological insights in HIVassociated cardiovascular disease in the era of highly active antiretroviral therapy. AIDS 2003;17 Suppl 1:S1-3.

  7. Barbaro G. Cardiovascular manifestations of HIV infection. J R Soc Med 2001;94(8):384-90.

  8. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002:106(11);1420-5.

  9. Polo R, Galindo MJ, Martínez E, Álvarez J y col. Recomendaciones de GEAM/SPNS sobre el tratamiento de las alteraciones metabólicas y morfológicas en el paciente con infección por VIH. Enferm Infecc Microbiol Clin 2006;24(2):96-117.

  10. Baum MK, Rafie C, Lai S, Xue L, et al. Coronary heart disease (CHD) risk factors and metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis 2006;2(3):173-9.

  11. Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology 2004;145(2):484-6.

  12. Panther LA. How HIV infection and its treatment affect the cardiovascular system: what is known, what is needed. Am J Physiol Heart Circ Physiol 2002;283(1):H1-4.

  13. Manfredi R. High-risk dysmetabolism disorders associated with HAART treated HIV disease, and reimbursement of lipidlowering drugs, in a clinical and a socio-economic perspective. AIDS Rev 2005;7(3):155-60.

  14. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care 2006;18(2):149-57.

  15. Iloeje UH, Yuan Y, L’Italien G, Mauskopf J, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005;6(1):37-44.

  16. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 2006;4(1):79-85.

  17. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005;5(3):255-62.

  18. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186(3):146-51.

  19. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61(23):2507-22.

  20. Tovar JM, Schering DB. Management of dyslipidemia in special populations. J Pharm Pract 2006;19(2):63-78.

  21. Hsue PY, Waters DD. What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation 2005;112(25):3947-57.

  22. Montessori V, Press N, Harris M, Akagi L, Montaner J. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170(2):229-38.

  23. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 2003;17 Suppl 1:S12-20.

  24. Andrade AC, Cotter BR. Endothelial function and cardiovasculardiseases in HIV infected patient. Braz J Infect Dis 2006;10(2):139-45.

  25. Restrepo CS, Diethelm L, Lemos JA, Velásquez E, et al. Cardiovascular complications of human immunodeficiency virus infection. Radiographics 2006;26(1):213-31.

  26. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(4):337-43.

  27. Sudano I, Spieker LE, Noll G, Corti R, et al. Cardiovascular disease in HIV infection. Am Heart J 2006;151(6):1147-55.

  28. Guillamón TL, Romeu FJ, Forcada SJ, Curós AA, et al. Afectación cardíaca en el SIDA. Rev Esp Cardiol 1997;50:721-8.

  29. Bruno R, Sacchi P, Filice G. Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy. AIDS 2003;17 Suppl 1:S83-87.

  30. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000;160(5):602-8.

  31. Valencia ME, Miró JM. Endocarditis in the setting of HIV infection. AIDS Rev 2004;6(2):97-106.

  32. Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J 2001;77(903):4-10.

  33. Currie PF, Boon NA. Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003;17 Suppl 1: S21-28.

  34. Fisher SD, Bowles NE, Towbin JA, Lipshultz SE. Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS 2003;17 Suppl 1:S29-35.

  35. Barbaro G, Di Lorenzo G, Benvenuto G, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti de AIDS. N Engl J Med 1998;339(16):1093-9.

  36. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol 2007;120(2):150-7.

  37. Velasquez EM, Glancy DL, Helmcke F, Kerut EK. Echocardiographic findings in HIV disease and AIDS. Echocardiography 2005;22(10): 861-6.

  38. Boccara F, Ederhy S, Janower S, Benyounes N, et al. Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. HIV Med 2005;6(4):240-4.

  39. Masiá MC, Bernal ME, Gutiérrez RF. Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral. Enferm Infecc Microbiol Clin 2006;24(10):637-48.

  40. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349(21):1993-2003.

  41. Friis-Moller N, Weber R, Reiss P, Thiébaut R, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17(8):1179-93.

  42. Law M, Friis-Moller N, Weber R, Reiss P, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003;4(1):1-10.

  43. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV infected men. AIDS 2003;17(17):2479-86.

  44. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003;17 Suppl 1:S162-9.

  45. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.

  46. Fitch KV, Anderson EJ, Hubbard JL, Carpenter SJ, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006;20(14):1843-50.

  47. Seaberg EC, Muñoz A, Lu M, Detels R, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19(9):953-60.

  48. Palacios R, Santos J, García A, Castells E, et al. Impact of highly active antiretroviral therapy on blood pressure in HIVinfected patients. A prospective study in a cohort of naive patients. HIV Med 2006;7(1):10-15.

  49. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006;20(7):1019-26.

  50. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005;143(4):282-92.

  51. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-Related pulmonary hypertension. Mt Sinai J Med 2006;73(7):1037-44.

  52. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118(4):1133-41.

  53. Bugnone AN, Viamonte M, García H. Imaging findings in human immunodeficiency virus-related pulmonary hypertension: report of five cases and review of the literature. Radiology 2002;223(3):820-7.

  54. Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. HIV-related cardiovascular disease and drug interactions. Am J Cardiovasc Drugs 2004;4(5):315-24.

  55. Jiménez FJ, Pinilla J, Repiso M, Labarga P. Bloqueo auriculoventricular completo en paciente tratado con lopinavir/ritonavir. Enferm Infecc Microbiol Clin 2002;20(8):418.

  56. Gil M, Sala M, Anguera I, Chapinal O, et al. QT prolongation and torsades des pointes in patients infected with human immunodeficiency virus and treated with metadone. Am J Cardiol 2003;92(8):995-7.

  57. Lucchini A, Barbaro G, Barbarini G. Methadone and QT prolongation in HIV-infected patients. Am J Cardiol 2004;94(1):147- 8.

  58. Dittmer DP, Vahrson W, Staudt M, Hilscher C, Fakhari FD. Kaposi’s sarcoma in the era of HAART–an update on mechanisms, diagnostics and treatment. AIDS Rev 2005;7(1):56-61.

  59. Lynen L, Zolfo M, Huyst V, Louis F, et al. Management of Kaposi’s sarcoma in resource-limited settings in the era of HAART. AIDS Rev 2005;7(1):13-21.

  60. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10(6):412-26.

  61. Singh AS, Dave DJ, Thanvi S, Atre DA, et al. Fatal secondary pulmonary hypertension due to cardiac involvement in aids-associated Burkitt’s lymphoma. Indian J Med Sci 2006;60(9):380-4.

  62. Klein SK, Slim EJ, de Kruif MD, Keller TT, et. al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005;63(4):129-36.

  63. Shen YM, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004;10(3):277-80.

  64. Sloand E. Hematologic complications of HIV Infection. AIDS Rev 2005;7(4):187-96.

  65. Cortez-Escalante JJ, Castro C, Romero GA, Matos L, Saif MW. Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo 2006;48(2):105-8.

  66. Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004 39(8):1214-22.




2020     |     www.medigraphic.com